The Role of Endoscopic Ultrasonography in the Diagnosis and Staging of Pancreatic Cancer

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2022 Mar 25

PMID 35326524

Authors

Ali Zakaria

Bayan Al-Share

Jason B Klapman

Aamir Dam

Affiliations

Soon will be listed here.

Abstract

Pancreatic cancer is the fourth leading cause of cancer-related death and the second gastrointestinal cancer-related death in the United States. Early detection and accurate diagnosis and staging of pancreatic cancer are paramount in guiding treatment plans, as surgical resection can provide the only potential cure for this disease. The overall prognosis of pancreatic cancer is poor even in patients with resectable disease. The 5-year survival after surgical resection is ~10% in node-positive disease compared to ~30% in node-negative disease. The advancement of imaging studies and the multidisciplinary approach involving radiologists, gastroenterologists, advanced endoscopists, medical, radiation, and surgical oncologists have a major impact on the management of pancreatic cancer. Endoscopic ultrasonography is essential in the diagnosis by obtaining tissue (FNA or FNB) and in the loco-regional staging of the disease. The advancement in EUS techniques has made this modality a critical adjunct in the management process of pancreatic cancer. In this review article, we provide an overall description of the role of endoscopic ultrasonography in the diagnosis and staging of pancreatic cancer.

Citing Articles

Clinical value of the nomogram model based on endoscopic ultrasonography radiomics and clinical indicators in identifying benign and malignant lesions of the pancreas.

Fan X, Huang J, Cai X, Maihemuti A, Li S, Fang W Front Oncol. 2025; 15:1504593.

PMID: 40046629 PMC: 11879810. DOI: 10.3389/fonc.2025.1504593.

Multidisciplinary Therapeutic Approaches to Pancreatic Cancer According to the Resectability Status.

Mauro A, Faverio C, Brizzi L, Mazza S, Scalvini D, Alfieri D J Clin Med. 2025; 14(4).

PMID: 40004698 PMC: 11856188. DOI: 10.3390/jcm14041167.

Informatics strategies for early detection and risk mitigation in pancreatic cancer patients.

Jin D, Khan N, Gu W, Lei H, Goel A, Chen T Neoplasia. 2025; 60:101129.

PMID: 39842383 PMC: 11763847. DOI: 10.1016/j.neo.2025.101129.

The outcomes of endoscopic ultrasound-guided tissue acquisition for small focal liver lesions measuring ≤2 cm.

Takano Y, Tamai N, Yamawaki M, Noda J, Azami T, Niiya F DEN Open. 2024; 5(1):e70031.

PMID: 39439546 PMC: 11494021. DOI: 10.1002/deo2.70031.

Updated techniques and evidence for endoscopic ultrasound-guided tissue acquisition from solid pancreatic lesions.

Itonaga M, Ashida R, Kitano M DEN Open. 2024; 5(1):e399.

PMID: 38911353 PMC: 11190023. DOI: 10.1002/deo2.399.

References

Mornex F, Girard N, Delpero J, Partensky C . Radiochemotherapy in the management of pancreatic cancer--part I: neoadjuvant treatment. Semin Radiat Oncol. 2005; 15(4):226-34. DOI: 10.1016/j.semradonc.2005.04.008. View

Varadhachary G, Tamm E, Abbruzzese J, Xiong H, Crane C, Wang H . Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy. Ann Surg Oncol. 2006; 13(8):1035-46. DOI: 10.1245/ASO.2006.08.011. View

Reni M . Neoadjuvant treatment for resectable pancreatic cancer: time for phase III testing?. World J Gastroenterol. 2010; 16(39):4883-7. PMC: 2957595. DOI: 10.3748/wjg.v16.i39.4883. View

Vernucci E, Abrego J, Gunda V, Shukla S, Dasgupta A, Rai V . Metabolic Alterations in Pancreatic Cancer Progression. Cancers (Basel). 2019; 12(1). PMC: 7016676. DOI: 10.3390/cancers12010002. View

Zhen D, Rabe K, Gallinger S, Syngal S, Schwartz A, Goggins M . BRCA1, BRCA2, PALB2, and CDKN2A mutations in familial pancreatic cancer: a PACGENE study. Genet Med. 2014; 17(7):569-77. PMC: 4439391. DOI: 10.1038/gim.2014.153. View

Zakharova O, Karmazanovsky G, Egorov V . Pancreatic adenocarcinoma: Outstanding problems. World J Gastrointest Surg. 2012; 4(5):104-13. PMC: 3364335. DOI: 10.4240/wjgs.v4.i5.104. View

Nagtegaal I, Odze R, Klimstra D, Paradis V, Rugge M, Schirmacher P . The 2019 WHO classification of tumours of the digestive system. Histopathology. 2019; 76(2):182-188. PMC: 7003895. DOI: 10.1111/his.13975. View

Pelaez-Luna M, Takahashi N, Fletcher J, Chari S . Resectability of presymptomatic pancreatic cancer and its relationship to onset of diabetes: a retrospective review of CT scans and fasting glucose values prior to diagnosis. Am J Gastroenterol. 2007; 102(10):2157-63. DOI: 10.1111/j.1572-0241.2007.01480.x. View

Ryan D, Hong T, Bardeesy N . Pancreatic adenocarcinoma. N Engl J Med. 2014; 371(11):1039-49. DOI: 10.1056/NEJMra1404198. View

10.

OReilly E, Perelshteyn A, Jarnagin W, Schattner M, Gerdes H, Capanu M . A single-arm, nonrandomized phase II trial of neoadjuvant gemcitabine and oxaliplatin in patients with resectable pancreas adenocarcinoma. Ann Surg. 2014; 260(1):142-8. PMC: 4520299. DOI: 10.1097/SLA.0000000000000251. View

11.

Kalser M, Barkin J, MacIntyre J . Pancreatic cancer. Assessment of prognosis by clinical presentation. Cancer. 1985; 56(2):397-402. DOI: 10.1002/1097-0142(19850715)56:2<397::aid-cncr2820560232>3.0.co;2-i. View

12.

Khalaf N, El-Serag H, Abrams H, Thrift A . Burden of Pancreatic Cancer: From Epidemiology to Practice. Clin Gastroenterol Hepatol. 2020; 19(5):876-884. PMC: 8559554. DOI: 10.1016/j.cgh.2020.02.054. View

13.

Jeon S, Lee J, Joo I, Lee D, Ahn S, Woo H . Magnetic resonance with diffusion-weighted imaging improves assessment of focal liver lesions in patients with potentially resectable pancreatic cancer on CT. Eur Radiol. 2018; 28(8):3484-3493. DOI: 10.1007/s00330-017-5258-1. View

14.

Ghadirian P, Simard A, Baillargeon J . Tobacco, alcohol, and coffee and cancer of the pancreas. A population-based, case-control study in Quebec, Canada. Cancer. 1991; 67(10):2664-70. DOI: 10.1002/1097-0142(19910515)67:10<2664::aid-cncr2820671043>3.0.co;2-k. View

15.

Paik W, Choi J, Park Y, Lee J, Park D . Optimal Techniques for EUS-Guided Fine-Needle Aspiration of Pancreatic Solid Masses at Facilities without On-Site Cytopathology: Results from Two Prospective Randomised Trials. J Clin Med. 2021; 10(20). PMC: 8540534. DOI: 10.3390/jcm10204662. View

16.

Michaud D, Vrieling A, Jiao L, Mendelsohn J, Steplowski E, Lynch S . Alcohol intake and pancreatic cancer: a pooled analysis from the pancreatic cancer cohort consortium (PanScan). Cancer Causes Control. 2010; 21(8):1213-25. PMC: 3098295. DOI: 10.1007/s10552-010-9548-z. View

17.

Palazzo L, Roseau G, Gayet B, Vilgrain V, Belghiti J, Fekete F . Endoscopic ultrasonography in the diagnosis and staging of pancreatic adenocarcinoma. Results of a prospective study with comparison to ultrasonography and CT scan. Endoscopy. 1993; 25(2):143-50. DOI: 10.1055/s-2007-1010273. View

18.

Lee L, Nieto J, Watson R, Hwang A, Muthusamy V, Walter L . Randomized Noninferiority Trial Comparing Diagnostic Yield of Cytopathologist-guided versus 7 passes for EUS-FNA of Pancreatic Masses. Dig Endosc. 2015; 28(4):469-475. DOI: 10.1111/den.12594. View

19.

Bakkevold K, Arnesjo B, Kambestad B . Carcinoma of the pancreas and papilla of Vater: presenting symptoms, signs, and diagnosis related to stage and tumour site. A prospective multicentre trial in 472 patients. Norwegian Pancreatic Cancer Trial. Scand J Gastroenterol. 1992; 27(4):317-25. DOI: 10.3109/00365529209000081. View

20.

Porta M, Fabregat X, Malats N, Guarner L, Carrato A, De Miguel A . Exocrine pancreatic cancer: symptoms at presentation and their relation to tumour site and stage. Clin Transl Oncol. 2005; 7(5):189-97. DOI: 10.1007/BF02712816. View